Alzheimer disease: The involvement of TREM2 R47H variant in Alzheimer disease confirmed, but mechanisms remain elusive.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Investigation of pathology, expression and proteomic profiles in human TREM2 variant postmortem brains with and without Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2020
   Article
2. Innate immune activation in Alzheimer's disease.Annals of translational medicine · 2018
   Review
3. Mutation analysis of the MS4A and TREM gene clusters in a case-control Alzheimer's disease data set.Neurobiology of aging · 2016
   Article
4. Microbiome-generated amyloid and potential impact on amyloidogenesis in Alzheimer's disease (AD).Journal of nature and science · 2015
   Article

Corrections and comments

• Comment on
  The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease.2015

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as